beyond. We team's afternoon, our you therapeutic execution to successful to and position serious today. We [indiscernible] build therapeutic and forward diseases. us and neuromuscular and Thanks, patients advancement everyone, had leadership and Todd, of momentum for throughout carry medicines look areas, with program and deliver our a hematology, very I'm important area and rare this XXXX innovative good thank to joining focused proud us quarter, in and
and into detail it III distinct from of announced line a our will results Phase jump BELIEVE indications. as first This chronic statement discovered on team a for results more know, positive is is in have across we to positive immune minute. that recently As I exciting very trials internally therapeutic you our luspatercept. top this MEDALIST two
Presentations also Part Phase in We trials PAH. pipeline, underway, trial Charcot-Marie-Tooth wholly-owned the one trial and two of ACE-XXX's across initiated sotatercept FSHD. recent Phase Part dystrophy, recently for II CMT, in each we in patients or of milestones critical now II is or or achieved and pulmonary our PULSAR facioscapulohumeral muscular arterial including with the disease, hypertension,
Turning luspatercept now to hematology. and
benefits and Phase response robust and to Congress and II Annual ASCO MDS the duration trials news rates of ago, at in are long-term The along continue recent from highlight weeks for erythroid our The regulatory positive be reported diseases. line Phase of medical with and presented we results luspatercept, hematologic MEDALIST late-stage we updated Celgene, III for top trials. patients pivotal with first-in-class few long and to ongoing respectively. We X first agent defect also BELIEVE We to been half in for to maturation a key during the excited applications about data results II and in and Meeting safety multiple the lower-risk of XXXX III our partner, very EU And Phase our thrilled trials XXXX. maturation treat serious the the Phase submitted beta-thalassemia the late A were endpoints across U.S. had anticipated that luspatercept the EHA. met meeting beta-thalassemia, MDS, we in submit syndromes, plan myelodysplastic all data trials risk and primary in and XXXX. These patient the collaboration future secondary low intermediate recently favorable will transfusion-dependent profile. to or presentation XXrd with
studies meaningful through reduction. continue cell X hemoglobin We treatment transfusion to patients continue to on multiple clinically who sustain blood and be encouraged remaining and in both increases observe red years in
trial, COMMANDS the will luspatercept. And In MDS myelofibrosis. of in who trials continue care [indiscernible]. current invest versus are have with ongoing expanding head-to-head of treatment luspatercept [indiscernible] standard across lower-risk the with X in overall X the the in beta-thalassemia III We start market we showing evaluate COMMANDS indications with of the superiority MDS, we Phase patients opportunity trial, and to a upcoming clinical with goal
We also ongoing non-transfusion-dependent two with II trials myelofibrosis. in have patients beta-thalassemia Phase and
anemias. I've effect, As to evaluating positive a hematologic chronic and top stated our number luspatercept Celgene the Acceleron potential luspatercept for two addition are development. corporate clinical opportunities Considering the currently in priority leadership be distinct X advancing indications platform is building treatment anemia. to diseases, the in has before, in To chronic that and of in actively a results
from to the plans. availability fully goal development clinical expanded is maximize anemia to and luspatercept's suffering Our through management many patients lifecycle
we that With XXX,XXX estimate address alone, has indications over the EU. under to potential U.S. the patients and luspatercept in development the current
you with many patients can anemia. significant as a is affect there of So chronic luspatercept for to the see, opportunity lives
development Before I want in organization. turn clinical over highlight to I hires X our presentation, to key also
Acceleron therapeutic our Medical Janethe Pena as First, leading He years over for including until will pleased I Novartis pipeline recently our PAH to at clinical Janethe senior the Group. to over Pulmonary development. comes additional for At investigate and clinical of responsible she most time presentation indications. for Robert and in XX pulmonary riociguat us Zeldin. was was from Pena discuss at we industry recently in roles Chief Robert from Medical Merck, will indications led the potential Ablynx instrumental Head as will advancing pipeline. important and company corporate and Clinical clinical pulmonary He he the where neuromuscular who an pass the trials experience, area Pulmonary. as our pulmonary now Bayer the quarter. luspatercept leading led Development trials our several brings to of the strategy she the welcome Dr. by Bayer, introduce advance joins us to hypertension I'm of progress Officer, in I development be joins welcome acquired [indiscernible] to new our FDA. of and and where also Chief want served Robert Officer Sanofi.
